ClinicalTrials.gg
RecruitingNCT06797973MOTHERUpdated Sep 11, 2026

Efficacy and Safety of Intrathecal Morphine for Postoperative Pain Management Following Planned Caesarean Section

A Phase 4 interventional study of Intrathecal Morphine and Placebo (Sodium Chloride Injection, 0.9%) in Caesarean Section and Postoperative Pain, sponsored by Anne Juul Wikkelsø. Recruiting at 9 sites in Denmark. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Anne Juul Wikkelsø · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,312
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies testing morphine in Pain, Postoperative — 18 open to participants now, 21 under way, 1 of them phase 3. Morphine · Pain, Postoperative.

Planned enrollment
Largest of 97
1,312 · median 90
Started
2025
with 10 others
Phase 4
42 of 97
7 open now
Primary completion
2027-05
later than 13 of 20 live
Registered
78th of 97
by date

Among the 97 studies testing morphine in Pain, Postoperative, this one has the largest planned enrollment, is one of 11 that started in 2025, is one of 42 in phase 4, reaches primary completion later than 13 of the 20 other live ones, and was the 78th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

18 of the 97 studies testing morphine in Pain, Postoperative are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About morphine

Morphine: first FDA approval 1984 (DURAMORPH PF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing morphine in Pain, Postoperative, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if morphine added to the spinal anaesthesia can improve postoperative pain treatment for patients undergoing caesarean section, without increasing the risk of serious adverse events in mother and baby.

The main questions it aims to answer are:

  • Is the treatment effective in preventing postoperative pain?
  • Is the treatment safe for both mother and baby?

Participants will be given a normal spinal anaesthesia with addition of either morphine or sodium chloride (inactive substance). All participants will receive standard postoperative pain treatment, including morphine tablets as needed. Researchers will collect data from the electronic medical record and ask the participants to fill out questionnaires about pain levels and possible side effects.

Read the detailed description

BACKGROUND AND OBJECTIVE:

Caesarean section is surgical procedure associated with moderate to severe postoperative pain, which can negatively affect recovery, mother-child bonding and the initiation of breastfeeding. Intrathecal morphine may offer pain relief for up to 24 hours, and is widely implemented and recommended as part of multimodal postoperative pain management. Despite the widespread use, there is limited evidence for the balance between benefits and harms of low-dose intrathecal morphine in patients undergoing caesarean section.

The objective of the trial is to evaluate analgesic efficacy as well as maternal and neonatal safety associated with addition of low-dose (80 µg) intrathecal morphine versus placebo to standard multimodal postoperative pain management in patients undergoing planned caesarean section.

The trial is a superiority, investigator-initiated, pragmatic, randomised, blinded, placebo-controlled multicentre trial.

TRIAL SIZE: A total of 1,312 participants is required to show/reject a 35% relative increase in the composite co-primary safety outcome, with an estimated baseline incidence of 21% without intrathecal morphine and a power of 80%. We adjust statistically for having two primary outcomes by using an alpha of 2.5%. We reach a power of 99.9% for the co-primary outcome of pain score with an estimated mean Numeric Rating Scale (0-10) of 4.88, standard deviation of 2.0 and relevant mean difference of 1.0.

ETHICAL CONSIDERATIONS: Intrathecal morphine for caesarean delivery represents a common medical practice which is not supported by robust evidence. High-quality data on efficacy and safety of the treatment will enable clinicians to tailor postoperative pain treatment to each patient, thus improving care for future patients. Choosing low-dose morphine minimises the risk of adverse effects, and all trial participants will receive standard multimodal pain treatment. There is no evidence of any harmful neonatal effects. All trial participants will give informed consent, and the trial will adhere to the Declaration of Helsinki as well as national and international standards of good clinical practice.

PLANNED SUBSTUDIES:

  • Incidence of desaturation and bradypnea during the first 24 hours following surgery, assessed using continuous wireless respiratory monitoring in a subpopulation of 100 patients at 3 trial sites.
  • Efficacy and safety of intrathecal morphine in participant subgroups: The influence of different pre-existing factors on the primary outcomes
03

Conditions studied

  • Caesarean Section
  • Postoperative Pain

Browse trials for

Keywords

  • Caesarean section
  • Cesarean section
  • Cesarean delivery
  • Caesarean delivery
  • Postoperative pain
  • Intrathecal morphine
  • Spinal morphine
  • elective caesarean
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years
  • Singleton pregnancy
  • Scheduled for planned caesarean section performed under spinal anaesthesia
  • Written

Exclusion criteria

Exclusion Criteria:

  • Allergy to or towards trial medication
  • Patients planned for postoperative epidural due to expected difficult postoperative pain management
  • Patients planned for combined spinal-epidural as primary anaesthesia
  • Inability to understand and read Danish
  • Previous inclusion in the trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,312 participants (estimated)

Study arms

  • Experimental
    Intrathecal morphine

    Drug: Intrathecal Morphine

  • Placebo comparator
    Placebo

    Drug: Placebo (Sodium Chloride Injection, 0.9%)

Interventions

  • DrugMorphineStudies of MorphineMorphine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    80 μg preservative-free morphine (0.2 ml) added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl

  • DrugPlacebo (Sodium Chloride Injection, 0.9%)

    0.2 ml of isotonic sodium chloride added to a single-shot spinal anaesthesia consisting of 11.5 mg hyperbaric bupivacaine and 10 μg fentanyl.

06

What researchers measure

Primary outcomes

  1. Level of pain when mobilising from supine to sitting position within 24 hours

    Longitudinal measurements of NRS (0-10) at 6, 12, 18 and 24 hours with most focus on the 24-hour pain level

    Time frame: 6, 12, 18 and 24 hours following spinal anaesthesia

  2. Maternal and neonatal serious adverse events

    Binary composite outcome: 1. Death of either participant or neonate within 7 days 2. Participants with clinically significant respiratory depression within 24 hours, defined as respiratory depression documented in the electronic medical record, e.g. need for airway management or pharmacological intervention (subjective assessment by treating clinician, validated by 2 investigators) 3. Neonates needing admission to neonatal intensive care unit within 48 hours 4. Hospitalisation of either participant or neonate within 7 days after discharge 5. Participants with severe vomiting or nausea within 24 hours, defined as ≥5 points on the 'Simplified postoperative nausea and vomiting impact scale'63 at any time point (6, 12, 18 and 24 hours)

    Time frame: Within 7 days from discharge

Secondary outcomes

  1. Opioid consumption within 24 hours

    Mg oral morphine equivalents

    Time frame: Within 24 hours following spinal anaesthesia

  2. Morphine associated adverse effects within 24 hours

    Binary composite outcome: participants experiencing either: 1. Vomiting (patient reported, yes/no) 2. Nausea 3. Dizziness 4. Pruritus Nausea, dizziness, and pruritus is assessed as "none", "little", "moderate", or "severe" with patients reporting "moderate" or "severe" categorised as having a positive outcome 5. Urinary retention, defined as need for re-catheterisation within 24 hours

    Time frame: Within 24 hours following spinal anaesthesia

  3. Obstetric quality of recovery score at 24 hours

    Obs-QoR-10 (0-100)

    Time frame: Within 24 hours following spinal anaesthesia

  4. Participants satisfaction with postoperative pain-treatment during the first 24 hours

    NRS 0-10

    Time frame: Within 24 hours following spinal anaesthesia

  5. Established breastfeeding at 30 days

    Proportion of neonates being exclusively breastfed at 30 days

    Time frame: 30 days from surgery

Other outcomes

  1. Serious adverse events, pain at 24 hours and opioid consumption, compared using Win Ratio

    A composite outcome analysed using Win Ratio, consisting of 1. Maternal and neonatal serious adverse events (as defined in the primary outcome) 2. Level of pain when mobilising from supine to sitting position at 24 hours (NRS 0-10) 3. Opioid consumption within 24 hours (mg oral morphine equivalents)

    Time frame: Within 7 days from discharge

  2. Overall severity of pruritus within 24 hours

    NRS 0-10

    Time frame: Within 24 hours following spinal anaesthesia

  3. Pharmacological treatment for opioid-related adverse effects within 24 hours

    Dexametasone, dosage (mg) 5-HT3 receptor antagonists, type, dosage (mg) Dopamine receptor antagonists, type, dosage (mg) Droperidol, dosage (mg) Antihistamines, type, dosage (mg) Pethidine, dosage (mg) Naloxone, dosage (mg) Clonidine, dosage (mg)

    Time frame: Within 24 hours following spinal anaesthesia

  4. Ability to mobilise independently

    Proportion of participants able to mobilise independently at 6, 12, 18 and 24 hours

    Time frame: 6, 12, 18 and 24 hours following spinal anaesthesia

  5. Level of pain at rest within 48 hours

    Longitudinal measurements of NRS (0-10) at 6, 12, 18, 24 and 48 hours

    Time frame: 6, 12, 18, 24 and 48 hours following spinal anaesthesia

  6. Opioid consumption within 48 hours

    Mg oral morphine equivalents

    Time frame: Within 48 hours following spinal anaesthesia

  7. "Rescue" supplemental pain treatment with truncal nerve block or epidural within 24 hours

    Binary composite outcome: participants receiving either an unplanned postoperative truncal nerve block or epidural analgesia within 24 hours

    Time frame: Within 24 hours following spinal anaesthesia

  8. Level of pain when mobilising from supine to sitting position at 48 hours

    NRS 0-10

    Time frame: Within 48 hours following spinal anaesthesia

  9. Total consumption of non-opioid analgesic medication (paracetamol, NSAIDs) within 24 hours and 48 hours

    Paracetamol, dosage (mg) NSAIDs, type, dosage (mg)

    Time frame: Within 24 and 48 hours following spinal anaesthesia

  10. Intraoperative nausea, vomiting and pruritus

    Binary composite outcome: participants experiencing either 1. Intraoperative nausea 2. Intraoperative vomiting 3. Intraoperative pruritus Nausea and pruritus are assessed as "none", "little", "moderate", or "severe" with patients reporting "moderate" or "severe" categorised as having a positive outcome. Vomiting is assessed as yes/no. Intraoperative is defined as from administration of spinal anaesthesia until the patient is leaving the operating room

    Time frame: During surgery

  11. Overall severity of pain within 24 hours (ObsQoR-10)

    NRS 0-10

    Time frame: Within 24 hours following spinal anaesthesia

  12. Overall severity of nausea/vomiting within 24 hours (ObsQoR-10)

    NRS 0-10

    Time frame: Within 24 hours following spinal anaesthesia

  13. Overall severity of dizziness within 24 hours (ObsQoR-10)

    NRS 0-10

    Time frame: Within 24 hours following spinal anaesthesia

  14. Overall severity of shivering within 24 hours (ObsQoR-10)

    NRS 0-10

    Time frame: Within 24 hours following spinal anaesthesia

  15. Overall feeling of being comfortable within 24 hours (ObsQoR-10)

    NRS 0-10

    Time frame: Within 24 hours following spinal anaesthesia

  16. Overall ability to mobilise independently within 24 hours (ObsQoR-10)

    NRS 0-10

    Time frame: Within 24 hours following spinal anaesthesia

  17. Overall ability to independently hold infant within 24 hours (ObsQoR-10)

    NRS 0-10

    Time frame: Within 24 hours following spinal anaesthesia

  18. Overall ability to nurse/feed infant independently within 24 hours (ObsQoR-10)

    NRS 0-10

    Time frame: Within 24 hours following spinal anaesthesia

  19. Overall ability to handle personal hygiene within 24 hours (ObsQoR-10)

    NRS 0-10

    Time frame: Within 24 hours following spinal anaesthesia

  20. Overall feeling of being in control within 24 hours (ObsQoR-10)

    NRS 0-10

    Time frame: Within 24 hours following spinal anaesthesia

  21. Length of hospital stay

    Total length of primary hospital stay (hours)

    Time frame: Within 7 days from discharge

  22. Readmission or unplanned hospital re-attendance within 7 days

    Binary composite outcome: participants needing either: 1. Hospital readmission within 7 days 2. Re-attendance (unplanned hospital out-patient consultation) within 7 days

    Time frame: Within 7 days following surgery

  23. Failed or insufficient spinal anaesthesia

    Binary composite outcome: participants needing either: 1. Conversion to general anaesthesia 2. Repeated neuraxial procedure 3. Supplemental intraoperative pain treatment

    Time frame: Within 24 hours following spinal anaesthesia

  24. Hospital-free days within 7 days

    Number of days out of hospital for both participant and neonate within 7 days

    Time frame: Within 7 days following surgery

  25. Ogilvie's syndrome/ileus within 7 days

    Proportion of participants with Ogilvie's syndrome/ileus that requires surgery or treatment with neostigmine within 7 days

    Time frame: Within 7 days following surgery

  26. Apgar score at 5 minutes following birth

    0-10

    Time frame: 5 minutes following birth

  27. Apgar score <7 at 5 minutes following birth

    Proportion of neonates with Apgar score \<7 at 5 minutes following birth

    Time frame: 5 minutes following birth

  28. Neonatal need for respiratory support within 48 hours

    Proportion of neonates needing respiratory support within 48 hours, defined as either: 1. Continuous positive airway pressure treatment 2. Positive pressure ventilation 3. HNF (high nasal flow) 4. Intubation 5. Oxygen therapy

    Time frame: Within 48 hours following birth

  29. Neonatal sedation resulting in failed breast-/bottle feeding within 48 hours

    Proportion of neonates not being breastfed or bottle fed due to neonatal sedation, corresponding to L=0 (too sleepy or reluctant, no sustained latch or suck achieved) on the LATCH scoring system

    Time frame: 24 and 48 hours following birth

  30. Neonatal hospitalisation within 24 hours after discharge

    Proportion of neonates hospitalised within 24 hours after discharge of participant

    Time frame: 24 hours after discharge

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data supporting the findings of this study are available from the corresponding author in accordance with Danish law and upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2027, 22 months after the start.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 22 months is above that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2025
First posted
Jan 29, 2025
StartActual
Jul 15, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
Jun 30, 2027
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06797973
Lead sponsor
Anne Juul Wikkelsø
Responsible party
Anne Juul Wikkelsø (Associate Professor, Senior Consultant, PhD, Zealand University Hospital) — Sponsor-investigator
First posted
Jan 29, 2025
Start date
Jul 15, 2025
Primary completion
May 31, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Sep 11, 2026

Study contacts

Anneline B Seegert, MD
Contact
ansee@regionsjaelland.dk
+4547326397
Anne J Wikkelsø, MD, PhD
Contact
awik@regionsjaelland.dk
+4547325046

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Morphine

Start the discussion